WO2014139476A8 - Rsv融合蛋白的表位以及识别其的抗体 - Google Patents
Rsv融合蛋白的表位以及识别其的抗体 Download PDFInfo
- Publication number
- WO2014139476A8 WO2014139476A8 PCT/CN2014/073505 CN2014073505W WO2014139476A8 WO 2014139476 A8 WO2014139476 A8 WO 2014139476A8 CN 2014073505 W CN2014073505 W CN 2014073505W WO 2014139476 A8 WO2014139476 A8 WO 2014139476A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epitope
- antibody
- fusion protein
- rsv fusion
- identifying same
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/777,275 US9856313B2 (en) | 2013-03-15 | 2014-03-17 | Epitope of RSV fusion protein and antibody recognizing the same |
CN201480013927.7A CN105722856B (zh) | 2013-03-15 | 2014-03-17 | Rsv融合蛋白的表位以及识别其的抗体 |
JP2015561931A JP6462599B2 (ja) | 2013-03-15 | 2014-03-17 | Rsv融合タンパク質のエピトープ及びそのエピトープを認識する抗体 |
AU2014231357A AU2014231357B2 (en) | 2013-03-15 | 2014-03-17 | Epitope of RSV fusion protein and antibody identifying same |
EP14765573.2A EP2975052B1 (en) | 2013-03-15 | 2014-03-17 | Epitope of rsv fusion protein and antibody identifying same |
CA2906960A CA2906960C (en) | 2013-03-15 | 2014-03-17 | Epitope of rsv fusion protein and antibody recognizing the epitope |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310082338 | 2013-03-15 | ||
CN201310082338.1 | 2013-03-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014139476A1 WO2014139476A1 (zh) | 2014-09-18 |
WO2014139476A8 true WO2014139476A8 (zh) | 2015-06-25 |
Family
ID=51535878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/073505 WO2014139476A1 (zh) | 2013-03-15 | 2014-03-17 | Rsv融合蛋白的表位以及识别其的抗体 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9856313B2 (zh) |
EP (1) | EP2975052B1 (zh) |
JP (1) | JP6462599B2 (zh) |
CN (1) | CN105722856B (zh) |
AU (1) | AU2014231357B2 (zh) |
CA (1) | CA2906960C (zh) |
WO (1) | WO2014139476A1 (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
CA2902877A1 (en) | 2013-03-13 | 2014-10-02 | Jeffrey Boyington | Prefusion rsv f proteins and their use |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
CN106496324B (zh) * | 2015-11-30 | 2020-01-14 | 天津昊免生物技术有限公司 | 一种抗呼吸道合胞病毒的全人源抗体 |
MY190320A (en) * | 2016-04-05 | 2022-04-13 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f proteins |
US11312761B2 (en) * | 2016-10-21 | 2022-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
EP3532489A4 (en) * | 2016-10-26 | 2020-07-08 | Cedars-Sinai Medical Center | ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES |
US11524994B2 (en) | 2016-12-19 | 2022-12-13 | Vanderbilt University | Antibodies to human respiratory syncytial virus protein F pre-fusion conformation and methods of use therefor |
CN108265079A (zh) * | 2017-01-02 | 2018-07-10 | 刘昕 | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 |
CN108300705B (zh) * | 2017-01-12 | 2021-10-22 | 厦门大学 | 稳定呼吸道合胞病毒融合蛋白的方法 |
JP7168938B2 (ja) | 2017-04-04 | 2022-11-10 | ユニヴァーシティ オブ ワシントン | パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用 |
EP3758747A1 (en) | 2018-02-28 | 2021-01-06 | University of Washington | Self-asssembling nanostructure vaccines |
CN110684747B (zh) * | 2018-07-06 | 2024-05-24 | 厦门大学 | 灭活及保存呼吸道合胞病毒的方法 |
CN111057718A (zh) * | 2018-10-17 | 2020-04-24 | 南京大学 | 一种稳定表达绿色荧光蛋白的egfp-sp2/0细胞株及其构建方法 |
KR102679227B1 (ko) * | 2019-02-28 | 2024-06-28 | 케이엠 바이올로직스 가부시키가이샤 | Rsv f/g 키메라 백신 |
EP4157341A1 (en) * | 2020-05-28 | 2023-04-05 | Sotira Covid, LLC | Peptides for covid-19 prevention and treatment |
WO2022268120A1 (en) * | 2021-06-22 | 2022-12-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-rsv antibodies and uses thereof |
AU2022404234A1 (en) * | 2021-12-06 | 2024-05-09 | Xiamen University | Antibody for recognizing rsv pre-f protein and use thereof |
CN116478296B (zh) * | 2022-10-17 | 2024-02-23 | 厦门大学 | 截短的呼吸道合胞病毒f蛋白及其用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
JP2005512044A (ja) | 2001-12-03 | 2005-04-28 | アブジェニックス・インコーポレーテッド | 結合特性に基づく抗体分類 |
EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
AU2009353693B2 (en) * | 2009-10-06 | 2016-07-21 | Medimmune Ltd | RSV-specific binding molecule |
CA3062786C (en) * | 2010-07-09 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
CN102210860B (zh) * | 2011-05-31 | 2012-11-21 | 昆明理工大学 | 一种结核分枝杆菌tb10.4-f1融合蛋白疫苗及制备方法 |
-
2014
- 2014-03-17 CA CA2906960A patent/CA2906960C/en active Active
- 2014-03-17 EP EP14765573.2A patent/EP2975052B1/en active Active
- 2014-03-17 US US14/777,275 patent/US9856313B2/en active Active
- 2014-03-17 JP JP2015561931A patent/JP6462599B2/ja active Active
- 2014-03-17 WO PCT/CN2014/073505 patent/WO2014139476A1/zh active Application Filing
- 2014-03-17 AU AU2014231357A patent/AU2014231357B2/en active Active
- 2014-03-17 CN CN201480013927.7A patent/CN105722856B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CA2906960A1 (en) | 2014-09-18 |
EP2975052B1 (en) | 2020-09-23 |
US9856313B2 (en) | 2018-01-02 |
JP2016516400A (ja) | 2016-06-09 |
WO2014139476A1 (zh) | 2014-09-18 |
JP6462599B2 (ja) | 2019-01-30 |
AU2014231357B2 (en) | 2018-06-14 |
AU2014231357A1 (en) | 2015-10-22 |
EP2975052A1 (en) | 2016-01-20 |
CA2906960C (en) | 2021-07-20 |
US20160031972A1 (en) | 2016-02-04 |
CN105722856A (zh) | 2016-06-29 |
CN105722856B (zh) | 2019-04-16 |
EP2975052A4 (en) | 2017-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014139476A8 (zh) | Rsv融合蛋白的表位以及识别其的抗体 | |
EP3308798A3 (en) | Polypeptides and antibodies for treating hbv infection and related diseases | |
WO2015179691A3 (en) | Cell penetrating peptides and methods of making and using thereof | |
WO2015063611A3 (en) | Albumin variants and uses thereof | |
JP2013172734A5 (zh) | ||
MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
IN2014KN01714A (zh) | ||
WO2016100807A3 (en) | Human antibodies to influenza hemagglutinin | |
WO2015061416A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
RU2018132044A (ru) | Антитела против тау | |
CL2015001314A1 (es) | Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; y uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada (div. sol. n° 679-14). | |
WO2013184976A3 (en) | Compositions and methods for antigen-specific tolerance | |
WO2015143123A3 (en) | Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof | |
EP3363458A3 (en) | A peptide | |
WO2014136064A3 (en) | Immunogenic fusion polypeptides | |
MX340796B (es) | Composiciones y procedimientos antigenicos del virus respiratorio sincitial. | |
PE20190733A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
WO2013098755A3 (en) | Anticancer fusion protein | |
MX2015016627A (es) | Vacuna para la malaria. | |
MX339203B (es) | Proteina de fusion anticancer. | |
WO2013150309A8 (en) | Clostridium difficile antigens | |
WO2016161415A3 (en) | Tnfrsf14/ hvem proteins and methods of use thereof | |
WO2014144621A3 (en) | Modified fc fusion proteins | |
NZ749998A (en) | Tfpi inhibitors and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14765573 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2015561931 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2906960 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14777275 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014765573 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014231357 Country of ref document: AU Date of ref document: 20140317 Kind code of ref document: A |